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ORIGINAL ARTICLE
A redox state-dictated signalling pathway deciphers the
malignant cell speciﬁcity of CD40-mediated apoptosis
CJ Dunnill1, K Ibraheem1, A Mohamed1, J Southgate2 and NT Georgopoulos1
CD40, a member of the tumour necrosis factor receptor (TNFR) superfamily, has the capacity to cause extensive apoptosis in
carcinoma cells, while sparing normal epithelial cells. Yet, apoptosis is only achieved by membrane-presented CD40 ligand
(mCD40L), as soluble receptor agonists are but weakly pro-apoptotic. Here, for the ﬁrst time we have identiﬁed the precise
signalling cascade underpinning mCD40L-mediated death as involving sequential TRAF3 stabilisation, ASK1 phosphorylation, MKK4
(but not MKK7) activation and JNK/AP-1 induction, leading to a Bak- and Bax-dependent mitochondrial apoptosis pathway. TRAF3 is
central in the activation of the NADPH oxidase (Nox)-2 component p40phox and the elevation of reactive oxygen species (ROS) is
essential in apoptosis. Strikingly, CD40 activation resulted in down-regulation of Thioredoxin (Trx)-1 to permit ASK1 activation and
apoptosis. Although soluble receptor agonist alone could not induce death, combinatorial treatment incorporating soluble CD40
agonist and pharmacological inhibition of Trx-1 was functionally equivalent to the signal triggered by mCD40L. Finally, we
demonstrate using normal, ‘para-malignant’ and tumour-derived cells that progression to malignant transformation is associated
with increase in oxidative stress in epithelial cells, which coincides with increased susceptibility to CD40 killing, while in normal cells
CD40 signalling is cytoprotective. Our studies have revealed the molecular nature of the tumour speciﬁcity of CD40 signalling and
explained the differences in pro-apoptotic potential between soluble and membrane-bound CD40 agonists. Equally importantly, by
exploiting a unique epithelial culture system that allowed us to monitor alterations in the redox-state of epithelial cells at different
stages of malignant transformation, our study reveals how pro-apoptotic signals can elevate ROS past a previously hypothesised
‘lethal pro-apoptotic threshold’ to induce death; an observation that is both of fundamental importance and carries implications for
cancer therapy.
Oncogene advance online publication, 21 November 2016; doi:10.1038/onc.2016.401
INTRODUCTION
CD40 is a member of the tumour necrosis factor receptor (TNFR)
superfamily and ligation by its cognate ligand CD40L (CD154)
plays a central role in the functioning of the immune system.1
CD40 signalling primes immunocytes for humoral and cell-
mediated responses and induces secretion of pro-inﬂammatory
cytokines by epithelial cells.1,2 A key feature of CD40-mediated
signalling is the exquisite context-speciﬁcity that deﬁnes func-
tional outcome; this is exempliﬁed in B lymphocytes, where CD40
signalling elicits bimodal growth-regulatory effects deﬁned by
cellular differentiation and transformation stage. In resting normal
B cells, CD40 signalling invokes proliferative responses, whereas
activated B cells are growth-inhibited.3 Similarly, whereas CD40
signalling is mitogenic and contributes to chemotherapy resis-
tance in low-grade B cell malignancies, in high-grade malignan-
cies, CD40 ligation induces growth arrest and/or apoptosis.4
CD40 is expressed on a variety of cells of non-lymphoid origin,
including ﬁbroblasts, endothelial and epithelial cells and the effect
of CD40 activation in such cells is equally context-speciﬁc. In
addition to cytokine/chemokine secretion,5,6 CD40 ligation may
result in cell proliferation, cytostasis or apoptosis, depending on
the cell type and malignant state. These observations further
extend the exquisite contextual, if not paradoxical nature of CD40
signalling (discussed by Eliopoulos et al.7). The ability of CD40 to
induce cytostasis or apoptosis is highly dependent on the ‘quality’
of receptor engagement. Soluble CD40 agonists (recombinant
CD40L or agonistic antibody) are only cytostatic or weakly pro-
apoptotic and only rendered pro-apoptotic following pharmaco-
logical intervention, for instance when combined with protein
synthesis inhibitors8 or chemotherapeutic drugs.5,9 By contrast,
membrane-presented CD40L (mCD40L) is highly pro-apoptotic
and induces extensive apoptosis in carcinoma cells of a variety of
origins,8–16 irrespective of whether the ligand is presented to
target carcinoma cells on the surface of third-party cells8,13,16 or by
mCD40L-expressing naturally activated immunocytes.15 The ability
of mCD40L to speciﬁcally and efﬁciently kill malignant cells, while
sparing their normal cell counterparts, represents perhaps the
most remarkable property of the CD40-mCD40L dyad.
Although CD40 lacks both death domain and intrinsic kinase
activity, its activation induces a variety of signalling cascades via
TRAF interacting motif (TIM) domains.17 Previous reports have
associated the capacity of mCD40L to induce apoptosis over non-
apoptotic soluble agonists with its ability to stabilise TRAF3
expression.11,13 TRAF3 stabilisation allows activation of down-
stream mitogen activated protein kinases (MAPKs), which is
dependent upon the formation of lipid rafts.18,19 TRAF3 appears to
be responsible for JNK activation following CD40L-CD40
engagement11,13,18 and the apoptotic potential of JNK is only
reached by sustained activation during mCD40L-CD40 signalling.
Thus, mCD40L may elicit a stronger or more sustained signal than
1Department of Biological Sciences, School of Applied Sciences, University of Huddersﬁeld, Huddersﬁeld, UK and 2Jack Birch Unit of Molecular Carcinogenesis, Department of
Biology, University of York, York, UK. Correspondence: Dr NT Georgopoulos, Department of Biological Sciences, School of Applied Sciences, University of Huddersﬁeld,
Queensgate, Huddersﬁeld HD1 3DH, UK.
E-mail: N.Georgopoulos@hud.ac.uk
Received 25 January 2016; revised 8 September 2016; accepted 16 September 2016
Oncogene (2016), 1–14
www.nature.com/onc
soluble agonist due to its ability to invoke more efﬁciently a
predominantly caspase 9-dependent mitochondrial pathway.11,13
The sustained nature of JNK activation seems to be the lynchpin-
determinant of pro-survival versus pro-apoptotic functions20 and
JNK-mediated AP-1 induction results in apoptosis induction.21
There are two tiers of MAPK activation leading to JNK
phosphorylation during cell stress, including that of MAPKKs and
MAPKKKs.22 Apoptosis signalling kinase 1 (ASK1) is MAPKKK-
activated in response to high levels of intracellular reactive oxygen
species (ROS)23 and downstream of this, the MAPKKs MKK4 and
MKK7 are often critical in apoptosis induction.21,24 It remains
unknown which of these signalling axes is involved in CD40-
mediated JNK activation, or how this links to the activation
of the intrinsic (mitochondrial) apoptotic pathway (discussed
in Georgopoulos et al.13).
Collectively, in epithelial cells it appears that the outcome of
CD40 signalling depends on both the quality of CD40 receptor
engagement and the downstream threshold for apoptosis
induction that is inﬂuenced by malignant transformation
status.8,16 To understand the underpinning mechanisms for these
observations, we have utilised a well-characterised epithelial cell
culture system that permits study of carcinoma cells, their normal
epithelial counterparts, as well as isogenic ‘para-malignant’ cells,
i.e. cells carrying deﬁned genetic alterations that mimic cells
undergoing malignant transformation.25–27 We have identiﬁed a
ROS level-dictated, pro-apoptotic signalling cascade that provides
a molecular explanation for these two fundamental properties of
CD40. Using this unique model to directly compare normal and
para-malignant cells to malignant cells, this study provides
unifying molecular evidence for a redox state-dependent pro-
apoptotic ‘lethal pro-apoptotic threshold’ that has been hypothe-
sised to exist in epithelial cells.28,29
RESULTS
mCD40L, but not soluble CD40 agonist, initiates the mitochondrial
apoptotic pathway in malignant but not normal epithelial cells
Using a co-culture system for the ligation of CD40 by mCD40L,
that we had previously characterised,8,13,15 we conﬁrmed that
mCD40L induces apoptosis in carcinoma cells (EJ and HCT116)
(Figure 1a), apoptosis involves caspase activation (Figure 1b) and
cell death requires caspase activity, as death was abrogated by the
pan-caspase inhibitor zVAD (Figure 1a). These assays involved co-
culture of mCD40L-expressing effector cells (3T3CD40L) with
epithelial cells in comparison with control co-cultures (3T3Neo
effectors) and results were normalised to epithelial cell-restricted
CK18 expression, as described in the Materials and Methods
section, to ensure that any background from the effector cells was
accounted for (Supplementary Figure 1). We additionally con-
ﬁrmed our ﬁndings using a DNA fragmentation assay where no
background interference from the effector cells was possible
during apoptosis detection (Supplementary Figure 2). Importantly,
soluble agonist (cross-linked, agonistic anti-CD40 mAb G28-5
which engages the CD40 receptor similarly to soluble trimeric
CD40L30) caused little detectable apoptosis in comparison to
mCD40L (Figure 1c). Our results were similar when we used an
Figure 1. mCD40L initiates a caspase-dependent mitochondrial apoptotic pathway in carcinoma cells but not normal cells. (a) mCD40L
induces apoptosis (expressed as fold change versus controls) in EJ and HCT116 carcinoma cells and death is caspase-mediated as
demonstrated by functional blockade of apoptosis using the pan-caspase inhibitor z-VAD (50 μM). In normal (NHU) epithelial cells, mCD40L did
not cause apoptosis and was cytoprotective. Bars represent mean fold change ± s.d. (n= 6). Of note, a 3-4-fold change in these apoptosis
detection assays corresponded to approximately ~ 80–85% dead cells in Annexin V-FITC/PI ﬂow cytometry assays.8 (b) mCD40L-induced
death in EJ and HCT116, but not normal NHU, cells and involves caspase-3/7 activation. Bars represent mean fold caspase activity ± s.d. (n= 5).
(c) Unlike mCD40L that causes extensive apoptosis in EJ and HCT116 carcinoma cells, soluble CD40 agonist (G28-5 agonistic anti-CD40
antibody) is only weakly pro-apoptotic. Bars represent mean fold change ± s.d. (n= 3). (d) CD40 ligation induces Bak and Bax expression (24 h)
in EJ carcinoma cells as shown by immunoblotting. By contrast, in NHU cells, a small reduction in expression of Bax and particularly Bak was
observed. CK18 detection was used for the comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to conﬁrm equal epithelial lysate
loading (as explained in the Methods). Of note, although equal amounts of protein were loaded for EJ and NHU cell lysates, normal cells
naturally expressed higher levels of CK18. Results are representative of three independent experiments. (e) Immunoblotting analysis of
cytoplasmic (Cyto) and mitochondrial (Mito) sub-cellular fractions following mCD40L-mediated CD40 ligation (24 h) in EJ cells. Western blot
conﬁrms induction of the mitochondrial apoptotic pathway by demonstrating mCD40L-mediated cytochrome c (Cyt c) release from the
mitochondria to the cytoplasm. Detection of Bcl-2 and GAPDH was used to conﬁrm successful sub-cellular fractionation. Results are
representative of at least two independent experiments.
Mechanisms of cancer cell-speciﬁc CD40 death
CJ Dunnill et al
2
Oncogene (2016) 1 – 14
independent, commercially-available agonist consisting of two
adjacent CD40L trimers, MegaCD40L (not shown). In contrast to
their malignant counterparts (EJ), normal human uro-epithelial
(NHU) cells were completely refractory to mCD40L-mediated
death; strikingly, in fact, CD40 ligation in NHU cells was
reproducibly cytoprotective, as it reduced background apoptosis
levels in culture (Figures 1a and b).
We determined that CD40 ligation by mCD40L caused rapid
induction of pro-apoptotic proteins Bak and Bax in EJ carcinoma
cells as early as 12 h post-ligation (not shown) and was sustained
at 24 h (Figure 1d). By contrast, no such effect was observed in
normal (NHU) cells, where a small reduction in Bak (and to a lesser
extent Bax) basal expression was detected following CD40 ligation
with mCD40L (Figure 1d), in agreement with the lack of apoptosis
and cytoprotection observed above (Figures 1a and b). Cell
fractionation experiments demonstrated that mCD40L induced
mitochondrial outer membrane permeabilisation (MOMP), evident
by the release of mitochondrial cytochrome c into the cytoplasm.
Moreover, mCD40L caused down-regulation of the anti-apoptotic
mitochondrial protein Bcl-2 (Figure 1e). Unlike mCD40L, soluble
CD40 agonists did not induce Bak/Bax expression or MOMP (not
shown). Therefore, combined with our previous ﬁndings that CD40
ligation does not involve signalling cross-talk with any known TNF
death receptors and/or their ligands,13 mCD40L-mediated apop-
tosis operates directly via the intrinsic mitochondrial pathway.
Activation of the JNK/AP-1 pathway and subsequent JNK/AP-1-
mediated upregulation of Bak and Bax are essential in mCD40L-
induced apoptosis
To determine the mechanism of Bak and Bax up-regulation as well
as ascertain the functional importance of these two pro-apoptotic
proteins, we examined whether the JNK/AP-1 pathway was critical,
as we have previously shown that JNK phosphorylation and JNK-
mediated downstream AP-1 activation are essential in mCD40L-
induced death,13 while JNK and AP-1 are often associated with
pro-apoptotic Bcl-2 protein expression.21 Pharmacological inhibi-
tion of the AP-1 transcription factor and, particularly, inhibition of
JNK abrogated CD40 killing (Figure 2a). We also found that
inhibition of JNK and AP-1 function diminished basal expression of
Bak and particularly Bax protein and caused complete blockade of
Bak and Bax induction following CD40 ligation (Figure 2b), thus
demonstrating that induction of Bak and Bax is fully-dependent
on the JNK/AP-1 pathway. To conﬁrm that Bak and/or Bax were
functionally involved in apoptosis, we prepared EJ carcinoma cells
stably expressing anti-Bak or anti-Bax short hairpin RNAs (shRNAs).
The shRNAs down-regulated basal protein expression and
prevented mCD40L-mediated Bak and Bax induction, respectively
(Figure 2c), while knockdown of both Bak and Bax resulted in
blockade of CD40-mediated death (Figure 2d).
Induction of TRAF3 and phosphorylation of ASK1 and MKK4 (but
not MKK7) are essential for JNK activation and mCD40L-mediated
apoptosis
Having previously demonstrated that CD40 ligation by mCD40L
(but not soluble agonist) rapidly induces TRAF3 expression at the
post-transcriptional level by inhibiting TRAF3 degradation and
shown that both TRAF3 and JNK are essential in apoptosis,13 we
investigated the pathway that underpins CD40 apoptosis in order
to identify receptor proximal and more distal signalling compo-
nents. As a candidate MAPKKK that might participate in signalling,
we investigated the involvement of ASK1 due to its role as a pro-
apoptotic factor in other systems, while downstream activation of
MKK4 and MKK7 was also examined since these two MAPKKs are
well established activators of JNK during the induction of
apoptosis.21
Ligation of CD40 by mCD40L in carcinoma cells caused rapid
induction of TRAF3 expression at 1.5 h (not shown) and
particularly 3 h (Figure 3a). Stabilisation of TRAF3 coincided with
phosphorylation of ASK1 (3 h) and this was followed by
phosphorylation of MKK4 and JNK (6 h); however no detectable
changes in MKK7 phosphorylation were observed. We conﬁrmed
that the activation of this MAPKKK-MAPKK-MAPK cascade was
followed by the induction of Bak and Bax at 12 h (not shown) and
24 h (Figure 3a). No changes in expression of total ASK1, MKK4/7
or JNK were observed. By contrast, TRAF3 knockdown abrogated
the activation of ASK1, subsequent phosphorylation of MKK4 and
JNK, and the induction of Bak and Bax expression, conﬁrming the
critical role of TRAF3 in deﬁning the outcome of CD40 signalling.
We then sought to ascertain the functional importance of ASK1
in this pathway and to conﬁrm that MKK4 rather than MKK7 was
responsible for subsequent JNK activation. Using kinase-speciﬁc
shRNAs to knock down expression of ASK1, MKK4 and MKK7,
respectively (Figure 3b), we found that loss of either ASK1 or
MKK4, but not MKK7, prevented JNK phosphorylation (Figure 3c)
while TRAF3 levels remained unaffected (not shown), thus
suggesting that downstream of TRAF3, mCD40L-mediated signal-
ling activates ASK1 and subsequently MKK4 to activate JNK, while
phospho-MKK7 is neither induced by (Figure 3a) nor does it
participate in CD40-mediated JNK activation (Figure 3c). Equally
importantly, knockdown of TRAF3, ASK1 and MKK4 but not MKK7
blocked CD40-mediated apoptosis as indicated by near complete
abrogation of effector caspase 3/7 activation (Figure 3d). Finally, to
conﬁrm our observations on the identity of the key components of
the mCD40L signalling pathway in carcinoma cells, we investi-
gated the role of these signalling components in an independent
cell line. Similarly to bladder EJ cells, we found that CD40 ligation
in colorectal adenocarcinoma HCT116 cells stabilised TRAF3
(Figure 3e), phosphorylated ASK1 but not MKK7 (not shown),
induced phosphorylation of MKK4 and upregulated pro-apoptotic
Bcl-2 member Bax (Figure 3e), while stable shRNA knockdowns
conﬁrmed that CD40 operated via a similar TRAF3-driven pathway
that depended on the activation of the intrinsic (mitochondrial)
pathway to induce cell death and caspase activation (Figure 4f).
mCD40L-mediated induction of reactive oxygen species (ROS) is
essential for apoptosis in carcinoma cells and is dependent on
signalling mediated through TRAF3 and NADPH oxidase (Nox)
As demonstrated in elegantly performed studies by Ichijo and
colleagues, the activation of ASK1 and subsequent induction of
apoptosis is dependent on its release from its biological inhibitor
Thioredoxin (Trx), following oxidation of Trx by reactive oxygen
species (ROS).23 Despite evidence supporting a role for ROS in
signalling and apoptosis triggered by the death receptor
subgroup of the TNFR family,31 the role of ROS in CD40 signalling
remains largely unknown particularly in epithelial cells.32 There-
fore, we examined whether CD40 signalling regulates cellular ROS
levels in order to activate ASK1 and provoke subsequent
apoptosis.
We ﬁrst compared the capacity of pro-apoptotic mCD40L and
non-apoptotic CD40 agonist (cross-linked G28-5 mAb)8,13 to
induce ROS production in carcinoma (EJ and HCT116) cells. We
found that mCD40L, but not soluble agonist, induced substantial
ROS production (Figure 4a and Supplementary Figure 3) and this
could be blocked by the ROS scavenger/antioxidant N-acetyl-L-
cysteine (NAC) (Figure 4a). Of note, the G28-5 antibody is active in
these cells, as evident by its ability to induce IL-8 secretion to the
same extent as mCD40L.12 ROS production was essential for
apoptosis, as treatment with NAC during CD40 ligation completely
inhibited mCD40L-mediated death (Figure 4b). The importance of
ROS was conﬁrmed by showing that inhibition of ROS with an
additional, independent antioxidant (propyl gallate) dose-
dependently blocked cell death (Supplementary Figure 6).
Although mitochondria are a major source of ROS, the release of
ROS occurred before evidence of apoptosis became apparent,
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indicating that the NADPH oxidase (Nox) protein complex might
be involved, as Nox represents a major source of ROS generation for
secondary messenger functions.33 Blockade of Nox fully abrogated
both mCD40L-mediated ROS induction (Supplementary Figure 7)
and mCD40L-mediated apoptosis, as seen with NAC (Figure 4b), thus
conﬁrming that the initial ROS trigger required for apoptosis was
Nox-generated. A previous report provided evidence that CD40
ligation in B cells can activate Nox and ROS production via
recruitment and activation of the regulatory (activatory) Nox-2
subunit p40phox to the CD40 cytoplasmic tail.34 Interestingly,
mCD40L, but not soluble CD40 agonist (not shown), induced
phosphorylation of p40phox in both EJ and HCT116 carcinoma
cells (Figure 4c) and in line with these observations, inhibition of
Nox blocked activation of pro-apoptotic molecules such as Bak
(Figure 4d). We conﬁrmed that the p40phox/Nox pathway was the
trigger for the ASK1-induced apoptotic pathway, as Nox blockade
fully inhibited phosphorylation of ASK1 and pro-apoptotic Bax
(Figure 4e).
We next examined the functional importance of TRAF3 in the
recruitment and activation of p40phox to initiate ROS and
subsequently pro-apoptotic signalling. TRAF3 knockdown attenu-
ated mCD40L-mediated p40phox phosphorylation (Figure 4c),
thus conﬁrming the critical role of TRAF3 in p40phox activation.
Therefore, in light of the observation that over-expressed TRAF3
can interact with p40phox,34 our ﬁndings provided evidence in
epithelial cells that endogenously activated TRAF3 by mCD40L-
triggered CD40 ligation can drive Nox activation by p40phox
phosphorylation. Strikingly, we also found that Nox itself could
inﬂuence the fate of TRAF3, as Nox inhibition prevented CD40-
mediated TRAF3 induction (Figure 4f), thus suggesting the
existence of a feedback loop between TRAF3 and Nox. Notably,
unlike Nox blockade, ROS inhibition (using NAC) did not prevent
TRAF3 induction (not shown) indicating that it is the direct
(physical or functional) involvement of p40phox/Nox and not just
ROS induction per se that is necessary for TRAF3 stabilisation.
CD40 ligation by mCD40L differentially modulates Thioredoxin-1
(Trx-1) protein levels in normal epithelial versus carcinoma cells
Our ﬁndings suggest that mCD40L-induced apoptosis requires
TRAF3-induced Nox activation via p40phox phosphorylation
(Figure 4) to trigger a pathway that operates via an ASK1-MKK4-
JNK signalling axis (Figure 3). CD40-mediated apoptosis is ROS- and
ASK1-dependent and it is well established that ASK1 activation
requires ROS-mediated Trx inactivation,23 while a direct interaction
between p40phox and Trx has been reported.35 We therefore
examined whether CD40 ligation by mCD40L had any effect on the
expression of Trx-1, the main Trx subunit regulating ASK1 function.
We determined the relative amounts of Trx-1 in carcinoma cells
following CD40 ligation compared to control (untreated) cells.
Interestingly, basal Trx-1 protein expression increased progres-
sively in carcinoma cells with time in culture (Figure 5a). Strikingly,
CD40 ligation by mCD40L fully (EJ cells, Figure 5a) or partially
(HCT116 cells, Figure 5c) inhibited the induction of Trx-1 by
actively inhibiting Trx-1 expression in carcinoma cells, and this
Figure 2. JNK/AP-1-induced Bak and Bax proteins are essential in CD40-mediated apoptosis. (a) mCD40L-mediated apoptosis in EJ carcinoma
cells is dependent on the activation of the JNK kinase and the AP-1 transcription factor as indicated by the blockade and attenuation of cell
death by the JNK inhibitor SP600125 (25 μM) and the AP-1 inhibitor NDGA (25 μM), respectively, in comparison to vehicle control (CON). Bars
represent mean fold change ± s.d. (n= 5). (b) Immunoblotting analysis demonstrates that the induction of Bak and Bax protein expression
following CD40 ligation (24 h) is dependent on JNK and AP-1, as the use of both JNK inhibitor SP600125 (25 μM) and AP-1 inhibitor NDGA
(25 μM) abrogates the induction of both Bak and Bax, in comparison to the untreated controls (CON). CK18 detection served as a loading
control. Results are representative of three independent experiments. (c) Retrovirus transduction was used to prepare EJ cell derivatives EJ-
Bak-KD and EJ-Bax-KD that stably express anti-Bak and anti-Bax shRNAs, respectively, as well as their isogenic controls (EJ-Con). Successful
knockdown was conﬁrmed by Western blotting for Bak and Bax in the appropriate cell lines following CD40 ligation (24 h), as Bak and Bax up-
regulation is prevented in the EJ-Bak-KD and EJ-Bax-KD lines, respectively, in comparison to the control shRNA-expressing EJ-Con cells. CK18
detection served as a loading control. Results are representative of two independent experiments. (d) CD40-mediated apoptosis is abrogated
by Bak and Bax knockdown as indicated by the blockade of caspase-3/7 activation in the EJ-Bak-KD and EJ-Bax-KD lines, in comparison to EJ-
Con. Bars represent mean fold caspase activity ± s.d. (n = 5).
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down-regulation of Trx-1 temporally coincided with the activation
of ASK1 (Figure 5b). By contrast, CD40 engagement by non-
apoptotic, soluble CD40 agonists (agonistic anti-CD40 mAb or
MegaCD40L) did not inhibit Trx-1 expression (not shown).
Importantly, this modulation of Trx-1 expression by CD40 was
cancer cell-speciﬁc, as we could only detect relatively low-level
Trx-1 expression in normal (NHU) epithelial cells and receptor
ligation by mCD40L had no detectable effect on Trx-1 expression
(Figure 5c). Of note, the inhibition of Trx-1 expression was
dependent on TRAF3 activation, as TRAF3 knockdown appeared to
prevent Trx-1 inhibition (Figure 5d).
Trx-1 inactivation renders CD40 signalling from non-apoptotic
CD40 agonist quantitatively and qualitatively equivalent to
membrane-bound CD40L
The ability of mCD40L to down-regulate Trx-1 protein levels was
striking and suggested that in addition to ROS induction, which
would inactivate Trx-1 to free ASK1 and permit apoptosis
activation, mCD40L uniquely also down-regulates Trx-1 to
diminish the capacity of malignant cells to cope with oxidative
stress. Moreover, in light of the lack of p40phox activation, ROS
induction or Trx-1 down-regulation by soluble CD40 agonist, we
hypothesised that the inability of soluble agonists to invoke cell
death could be attributed to their inability to engage CD40
sufﬁciently to induce TRAF313 and in parallel raise the levels of
ROS required to inactivate Trx-1 and permit ASK1-mediated
apoptosis (Figure 4).
To address this scenario, we tested the hypothesis that
pharmacological inhibition of Trx-1 using the highly-speciﬁc,
well-characterised irreversible inhibitor PX-1236,37 would synergise
with soluble CD40 agonist to induce apoptosis. Although higher
concentrations of PX-12 resulted in high cytotoxicity, initial pre-
titration experiments allowed us to determine concentrations of
PX-12 that demonstrated minimal cytotoxicity. When used
alone, Trx-1 inhibitor or soluble CD40 agonists (G28-5 mAb or
Figure 3. Induction of TRAF3 and phosphorylation of ASK-1 and MKK4 are essential in JNK-activation and CD40-mediated apoptosis.
(a) Retrovirus transduction was used to establish the EJ derivative line EJ-TRAF3-KD, which stably expresses an anti-TRAF3 shRNA, and its
isogenic control shRNA-expressing cell line EJ-Con. Immunoblotting experiments demonstrate that ligation of CD40 in the control cells
caused induction of TRAF3 expression (3 h), but this is signiﬁcantly attenuated in EJ-TRAF3-KD cells. Further Western blotting experiments
show that in EJ-Con, CD40 ligation triggers the phosphorylation of ASK-1 (3 h) as well as MKK4 (6 h) and JNK (6 h). No visible changes in MKK7
phosphorylation (6 h) were observed. These changes are followed by the induction of Bak and Bax (24 h). By contrast, TRAF3 knockdown
abrogates the activation of ASK-1, subsequent phosphorylation of MKK4 and JNK, as well as induction of Bak and Bax. CK18 detection was
used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to ensure equal loading. Time points are indicated on the right hand
side for clarity. Results are representative of three independent experiments. Of note, in all immunoblotting experiments, expression of
cytokeratin proteins (CK8 or CK18) was employed to conﬁrm equal loading rather than total unphosphorylated protein (as explained in the
Methods). (b) Retrovirus transduction was used to establish EJ cell line derivatives EJ-ASK1-KD, EJ-MKK4-KD and EJ-MKK7-KD that stably
express anti-ASK-1, anti-MKK4 and anti-MKK7 shRNAs, respectively. Immunoblotting experiments in these cell lines demonstrated that CD40-
mediated phosphorylation of ASK-1 (3 h) and MKK4 (6 h) is blocked by the respective shRNAs when compared to their isogenic control cells
(EJ-Con – as shown in (a) above as well as in Supplementary Figure 8), while basal phospho-MMK7 expression (6 h) is reduced. CK18 detection
was used to assess equal loading. Results are representative of at least two independent experiments. (c) Western blots for the detection of
phosphorylated JNK following CD40 ligation (6 h) in EJ-ASK1-KD, EJ-MKK4-KD and EJ-MKK7-KD demonstrate that shRNA-mediated
knockdown of ASK-1 and MKK4, but not MKK7, signiﬁcantly attenuates CD40-mediated p-JNK induction observed in control cells (EJ-Con in
Figure 2a above). CK18 detection was used to assess equal loading. Results are representative of two independent experiments. (d) CD40-
mediated apoptosis is abrogated by TRAF3, MKK4, ASK-1 knockdown as indicated by the blockade of caspase-3/7 activation in EJ-TRAF3-KD,
EJ-ASK1-KD and EJ-MKK4-KD cells, in comparison to EJ-Con. By contrast, MKK7 knockdown had no effect on apoptosis. Bars represent mean
fold caspase activity ± s.d. (n= 5). Results are representative of three independent experiments. (e) Immunoblotting experiments demonstrate
that ligation of CD40 in HCT116 cells triggers upregulation of TRAF3 (3 h), as well as phosphorylation of MKK4 (6 h) and JNK (6 h), which is
followed by the induction of Bax (12 h). CK8 detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to conﬁrm
equal loading. Results are representative of at least two independent experiments. (f) Retrovirus transduction was used to establish the
HCT116 derivative lines HCT116-TRAF3-KD and HCT116-Bax-KD, which stably express anti-TRAF3 and anti-Bax shRNA, respectively, and their
isogenic control shRNA-expressing cell line HCT116-Con. CD40-mediated apoptosis is attenuated by TRAF3 and Bax knockdown as indicated
by the blockade of caspase-3/7 activation in HCT116-TRAF3-KD and HCT116-Bax-KD cells, in comparison to HCT116-Con. Bars represent mean
fold caspase activity ± s.d. (n = 5).
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MegaCD40L) induced little apoptosis; however, combinations of
PX-12 inhibitor and soluble agonist were synergistic in inducing
extensive apoptosis in carcinoma cells (Figure 6b), comparable to
that observed following CD40 ligation by mCD40L (Figure 1). By
contrast, in normal (NHU) cells, neither the Trx-1 inhibitor nor the
soluble agonist caused any apoptosis, whereas their combination
was slightly cytoprotective (Figure 6a) and in striking similarity to
mCD40L (Figure 1a). Therefore, the combinatorial treatment of
PX-12 and soluble CD40 agonist induces extensive apoptosis in
carcinoma, but not normal cells, and is quantitatively equivalent to
mCD40L.
To determine if the combinatorial treatment triggered the same
molecular programme as entrained by mCD40L, we examined the
key apoptosis signalling mediators identiﬁed above. Importantly,
the combination of soluble CD40 agonist (G28-5 mAb) and Trx-1
inhibitor (PX-12) triggered substantial induction of TRAF3, which
was equivalent to that observed with mCD40L, whereas agonist or
inhibitor alone caused little or no TRAF3 induction, respectively
(Figure 6c). Moreover, similarly to mCD40L, apoptosis by
combinatorial treatment was inhibited by NAC, thus conﬁrming
the importance of ROS in cell death, whilst ASK1 was essential in
the induction of apoptosis as shRNA-mediated ASK1 knockdown
prevented apoptosis (Figure 6d), whilst we obtained similar
observations following TRAF3 knockdown (not shown). Therefore,
inhibition of Trx-1 function converted the non-apoptotic CD40
signal initiated by soluble agonist into a strongly pro-apoptotic
signal that caused death by an equivalent signalling mechanism
to that triggered by mCD40L.
CD40-mediated regulation of ROS and apoptosis in ‘para-
malignant’ and transformed versus normal epithelial cells provides
evidence for a critical redox state-associated pro-apoptotic
threshold
A feature of malignant cells is their ability to operate under
oxidative stress,38 with the suggestion that basal ROS deﬁnes a
Figure 4. mCD40L-induced ROS release is essential for apoptosis and is driven by TRAF3- and Nox-dependent signalling. (a) The levels of ROS
in EJ and HCT116 carcinoma cells were measured by H2DCFDA labelling, which was detected spectrophotometrically and expressed as fold
change relative to H2DCFDA-labelled untreated cells. Unlike cells treated with soluble agonist (10μg/ml cross-linked G28-5), mCD40L-treated
cells showed rapid induction of ROS (3 h) which was blocked by the ROS scavenger/antioxidant NAC (30 mM). Bars represent mean fold
increase in ROS ± s.d. (n = 6). In addition to spectrophotometric measurements, ROS induction by CD40 ligation was also detected by
H2DCFDA labelling and ﬂow cytometry, and representative results for HCT116 cells from at least two experiments are shown on the overlay
histogram on the right to compare controls (Con) versus mCD40L-treated cells (mCD40L). (b) mCD40L-mediated apoptosis in EJ and HCT116
carcinoma cells is blocked by both the antioxidant NAC (30 mM) and the pharmacological Nox inhibitor DPI (0.25 or 0.125 μM in EJ and
HCT116, respectively). Bars represent mean fold change ± s.d. (n = 6). (c) Immunoblotting experiments demonstrate that ligation of CD40 in EJ
(as shown in EJ-Con cells) and HCT116 cells triggers phosphorylation of the Nox subunit p40phox. The experiments also show that CD40-
mediated phosphorylation of p40phox is attenuated in TRAF3 shRNA-expressing cells (EJ-TRAF3-KD) in comparison to isogenic controls
(EJ-Con). Cytokeratin detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) in EJ derivatives (CK18) and HCT116
(CK8) cells, respectively, to ensure equal loading. Results are representative of at least two independent experiments. (d) Blockade of Nox by
the pharmacological inhibitor DPI (0.125 μM) completely inhibited mCD40L-mediated induction of Bak (24 h) in HCT116 cells. CK8 detection
was used to assess equal loading. Results are representative of two independent experiments. (e) Western blotting shows that
pharmacological inhibition of Nox by DPI (0.25 μM) blocks activation of ASK-1 (3 h) and subsequently Bax induction (24 h) by CD40 in EJ cells.
CK18 detection conﬁrmed equal loading. Results are representative of three experiments. (f) Nox blockade during CD40 ligation in HCT116
and EJ cells by treatment with DPI (as described in panels D and E, respectively), attenuated the induction of TRAF3 by mCD40L. Cytokeratin
detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) in EJ (CK18) and HCT116 cells (CK8), respectively, to
ensure equal loading. Results are representative of two independent experiments.
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‘lethal threshold’ that determines whether cytotoxic insults induce
apoptosis.29,39 Formal demonstration of such a threshold has been
hampered by the lack of appropriate epithelial models for the
study of normal cells and their transformed counterparts.28 Based
on the differences between pro- and non-apoptotic CD40 ligation,
a critical signalling threshold must be reached before CD40 can
induce death. As the ability of CD40 ligation to induce apoptosis is
closely associated with malignant transformation,8,13 it appears
that this threshold is altered during carcinogenesis and our results
implicate a critical role for ROS.
We exploited our well-characterised epithelial cell platform to
study how malignant transformation affects the susceptibility of
epithelial cells to pro-apoptotic signals8,16,27 and used CD40
signalling as a paradigm to demonstrate the existence of a redox
state-dependent pro-apoptotic threshold. We included three well-
characterised bladder cancer cell lines RT4, RT112 and EJ, which
represent a spectrum of bladder cancer grades and stages. RT4
represents a non-malignant well-differentiated line, RT112 a
moderately differentiated invasive cell line and EJ (T24 sub-line)
cells represent highly-malignant carcinoma cells. These cell lines
have been shown, both in vitro and in vivo, to faithfully
recapitulate the grade and stage of the tumours of origin.25,40 In
support of accumulating evidence suggesting that during
carcinogenesis cells gradually evolve to operate under oxidative
stress, we found that basal levels of ROS in these cell lines
correlated closely with the degree of anaplasty (malignancy), with
the highest amount of ROS observed in the most malignant
EJ cells and the lowest levels in the RT4 cell line (Figure 7a). When
these cells were exposed to extreme ROS levels by treatment
with H2O2, EJ was the most susceptible cell line and RT4 the
least susceptible (Figure 7b). Importantly, EJ was also the most
susceptible line to mCD40L-mediated apoptosis and RT4 the
least susceptible (Figure 7c). As RT112 cells are naturally CD40-
negative, we used a stable CD40-expressing derivative (RT112-
CD40).13,15 RT112-CD40 cells exhibited basal ROS levels equivalent
to RT112 cells (not shown) and were moderately susceptible to
mCD40L-mediated apoptosis (Figure 7c). Therefore, susceptibility
to artiﬁcially-induced intracellular ROS elevation in tumour cells
representing different malignant stages directly correlated with
susceptibility to mCD40L-triggered apoptosis.
To provide insight as to how malignant transformation directly
inﬂuences ROS, we examined basal ROS in normal (NHU) cells and
compared it to their malignant counterparts, as well as immortal
NHU derivatives that over-express the catalytic subunit of human
telomerase (HU-hTERT cells). We have shown previously that
despite being karyotypically normal, these cells have impaired
p16 function and progressively lose the ability to undergo
cytodifferentiation.26 Moreover, it has been suggested that hTERT
may increase basal ROS to sensitise cells to pro-apoptotic signals
during malignant transformation.41 Notably, the lowest basal ROS
Figure 5. CD40 ligation by mCD40L down-regulates Trx-1 protein levels in carcinoma but not normal epithelial cells. (a) Trx-1 protein
expression in EJ carcinoma cells was monitored by immunoblotting at the indicated time points following CD40 ligation. Although Trx-1
expression increased in cultures following resumption of growth after sub-culture (as seen in the controls, ‘–’), CD40 ligation by mCD40L fully
blocked Trx-1 expression (as seen in ‘+’ samples). CK18 detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to
ensure equal loading. Results are representative of three independent experiments. (b) Immunoblotting experiments show that CD40 ligation
triggers the phosphorylation of ASK-1 at 3 h which coincides with a reduction in Trx-1 expression (the results represent co-cultures of EJ cells
with mCD40L-expressing 3T3CD40L and control 3T3Neo ﬁbroblasts). 3T3CD40L- (3T3CD40L) and 3T3Neo-only (3T3Neo) cultures showed no
ASK-1 phosphorylation and EJ cells cultured alone (EJ alone) showed little (basal) ASK-1 phosphorylation. β-actin detection was used to ensure
equal loading. Results are representative of two independent experiments. (c) Trx-1 protein expression was determined in normal (NHU) and
malignant epithelial cells (EJ and HCT116) following treatment with mCD40L (24 h) by immunoblotting. In contrast to malignant cells where
CD40 ligation induced Trx-1 reduction, NHU cells expressed low levels of Trx-1 and CD40 appeared to have no effect on Trx-1 expression. CK18
(EJ) and CK8 (HCT116) detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to demonstrate equal loading. Of
note, as NHU cells naturally express higher levels of CK18 in comparison to malignant (EJ) cells, and to ensure that any differences in basal Trx-
1 protein expression were not artefactual, correct loading was conﬁrmed for urothelial cells by detection of β-actin, the levels of which were
similar in both cell types. Results are representative of two independent experiments. (d) Using immunoblotting, the levels of Trx-1 protein
were determined in EJ-TRAF3-KD and their isogenic controls (EJ-Con) following treatment with mCD40L (6 h). In contrast to control cells
where CD40 ligation induced a reduction in Trx-1 expression, EJ-TRAF3-KD cells maintained normal Trx-1 expression. CK18 detection was used
for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’) to ensure equal loading. Results are representative of two independent
experiments.
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was detected in normal epithelial cells and the highest in
carcinoma-derived cells, while hTERT-immortalised cells demon-
strated moderate expression (Figure 7d), thereby supporting
the notion that hTERT can raise basal ROS. Strikingly, unlike
carcinoma-derived cells which were highly susceptible to oxida-
tive stress, normal epithelial cells were completely refractory to
extreme ROS related stress (Figure 7e). By contrast, HU-hTERT cells
were more susceptible to treatment with H2O2 than their normal
cell counterparts but could withstand higher levels of oxidative
stress than carcinoma cells (Figure 7e). Importantly, when we
examined susceptibility to mCD40L-mediated apoptosis, we found
that HU-hTERT cells were nearly as susceptible to apoptosis as
Figure 6. Combination of pharmacological Trx-1 inhibitor and soluble CD40 agonist is pro-apoptotic, tumour-speciﬁc and functionally
equivalent to mCD40L. (a) Normal epithelial cells (NHU) were treated with either Trx-1 inhibitor PX-12 (4μM) or soluble CD40 agonist G28-5
mAb (10μg/mL) alone, or with combination of the two (‘PX-12+G28-5’) and apoptosis was assessed (see Methods). Neither the inhibitor nor
the agonist alone induced any apoptosis and nor did their combination, which was slightly cytoprotective. Bars represent mean fold change
± s.d. (n= 3). (b) Combinatorial treatment of EJ and HCT116 carcinoma cells with Trx-1 inhibitor (4μM) and soluble CD40 agonist (10μg/mL)
(‘PX-12+G28-5’) synergistically mediated extensive apoptosis, whereas treatment with either the inhibitor (PX-12) or agonist (G28-5) alone
caused little (EJ) or relatively low (HCT116) amounts of apoptosis. Bars represent mean fold change ± s.d. (n = 5). (c) Using immunoblotting,
the levels of TRAF3 protein were determined in malignant epithelial cells (EJ) treated with Trx-1 inhibitor PX-12 (2μM) or soluble CD40 agonist
G28-5 mAb (10μg/mL) alone, or with combination of the two (‘PX-12+G28-5’) (6 h). Solvent alone (DMSO) treated EJ cells (Control) were used
as a control for experiments involving soluble agonists, whereas controls (‘–’) versus mCD40L-treated cells (‘+’) representing 3T3Neo/EJ and
3T3CD40L co-cultures (6 h), respectively, were used to detect TRAF3 protein expression following mCD40L treatment. The results demonstrate
that CD40 agonist G28-5 mAb alone caused little TRAF3 induction, however its combination with PX-12 induced TRAF3 expression as strongly
as did mCD40L. (d) Apoptosis triggered by the combination of Trx-1 inhibitor and soluble CD40 agonist (as above) was inhibited by the
antioxidant NAC (30 mM) as well as by knockdown of ASK-1, as shown by the lack of apoptosis in ASK-1 shRNA expressing (EJ-ASK1-KD) cells
in comparison to their isogenic controls (EJ-Con). Bars represent mean fold change ± s.d. (n= 6).
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carcinoma-derived cells (Figure 7f), with mCD40L, but not soluble
agonist (not shown), engaging the intrinsic apoptotic pathway, as
was evidenced by the induction of Bax and particularly Bak
expression (Figure 7g). Collectively, our observations using normal,
‘para-malignant’ and carcinoma-derived epithelial cells suggest that
neoplastic and malignant transformation progressively raises basal
ROS and forces cells to operate under oxidative stress. As a
consequence, cells progressively become more susceptible to pro-
apoptotic, ROS-inducing signals, such as pro-apoptotic CD40 ligation.
DISCUSSION
Using an epithelial cell culture system encompassing carcinoma
cells of different grades and stages alongside normal epithelial
Figure 7. CD40-mediated modulation of ROS and apoptosis in normal, ‘para-malignant’ and transformed epithelial cells. (a) The basal levels of
ROS in the panel of bladder cancer cell lines RT4 (well-differentiated, non-malignant), RT112 (moderately-differentiated, non-malignant) and EJ
(undifferentiated, highly-malignant) were measured by H2DCFDA labelling. There was an apparent correlation between increased basal ROS
expression and degree of anaplasty, with EJ4RT1124RT4 cells. Bars represent average relative ﬂuorescence units (RFU) ± s.d. (n= 3). (b) The
RT4, RT112 and EJ cell lines were treated with the indicated concentrations of H2O2 and viability was assessed. The more anaplastic, malignant
cells EJ exhibited the highest degree of susceptibility to oxidative stress in comparison to the highly differentiated, non-malignant RT4 cells
that were the least susceptible. Bars represent mean % cell growth ± s.d. (n = 5). (c) Ligation of CD40 by mCD40L in the cancer cell lines
resulted in extensive apoptosis in the highly malignant EJ cells, whereas the non-anaplastic highly-differentiated RT4 cells showed relatively
low susceptibility to CD40 ligation. RT112 cells that were engineered to express the CD40 receptor showed moderate susceptibility to CD40-
mediated apoptosis. Bars represent mean % cell death ± s.d. (n = 3). (d) The basal ROS in normal (NHU) cells, para-malignant NHU derivatives
stably expressing hTERT (HU-hTERT) and the malignant cell line EJ were determined by H2DCFDA labelling and ﬂow cytometry. Representative
results of such analysis are shown in the overlay histogram (left), while the derived results for NHU, HU-hTERT, EJ and HCT116 from similar
analyses are presented as average MFI (right). Basal ROS was higher in hTERT-expressing epithelial cells in comparison to their normal
counterparts, but were lower than those observed in malignant (EJ and HCT116) cells. Bars represent mean MFI ± s.d. (n = 3). (e) NHU, HU-
hTERT, EJ and HCT116 cells were treated with the indicated concentrations of H2O2 and viability was assessed. The malignant cells EJ and
HCT116 exhibited the highest degree of susceptibility to oxidative stress in comparison to normal NHU cells which were nearly completely
refractory to the tested concentrations of H2O2. By contrast, the para-malignant HU-hTERT cells demonstrated signiﬁcant susceptibility to
oxidative stress, which was nevertheless lower than that of EJ and HCT116 cells. Bars represent mean % cell growth ± s.d. (n= 5). (f) Ligation of
CD40 by mCD40L caused substantial apoptosis in HU-hTERT cells, in comparison to their normal (NHU) counterparts that were refractory.
Apoptosis in normal and para-malignant cells was compared to EJ and HCT116 cells. Bars represent mean fold change ± s.d. (n = 5).
(g) Immunoblotting experiments show that CD40 ligation induces Bak and to a lesser extent Bax expression (24 h) in para-malignant
HU-hTERT cells in comparison to normal (NHU) cells. CK18 detection was used for comparison of controls (‘–’) versus mCD40L-treated cells (‘+’)
and conﬁrmed equal epithelial lysate loading. Results are representative of three independent experiments.
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counterparts and isogenic ‘para-malignant’ cells, we have
provided molecular explanation for two previously-described
features of CD40 ligation in epithelial cells: a) mCD40L induces
extensive carcinoma cell-speciﬁc apoptosis, whereas soluble
agonists do not, and b) a critical pro-apoptotic signalling threshold
must be reached for apoptosis to occur, which is closely linked
with malignant transformation.8,16 We found that mCD40L, but
not soluble agonist, utilises ROS elevation while concurrently
down-regulating anti-oxidant responses (Trx) to efﬁciently kill
malignant cells, by operating along a TRAF3-Nox/p40phox-ASK1-
MKK4-JNK signalling axis to induce the mitochondrial apoptotic
pathway (Figure 8). Using the CD40 system as a biological
paradigm, we have further provided evidence for the existence of
a ROS-deﬁned ‘lethal pro-apoptotic threshold’.
The degree of receptor cross-linking is critical in engaging the
CD40 apoptotic machinery adequately to induce cell death.
Despite the fact that soluble CD40 agonist is biologically active, for
instance, the G28-5 antibody can induce cytokine secretion, the
quality of the signal is important; both soluble agonist and
mCD40L can induce equivalent maximal IL-8 secretion in
carcinoma cells, yet only mCD40L induces secretion of GM-
CSF.12 This indicates fundamental, signal quality-related differ-
ences. This property of CD40 appears to be an important feature
shared within the TNF receptor family, as ‘‘signal quality’’ (i.e. the
degree of receptor activation or cross-linking) affects or deter-
mines the outcome of receptor ligation. Highly cross-linked
agonistic antibodies, cross-linked soluble recombinant ligands
and particularly membrane-presented ligand (achieved by co-
culture of target cells with growth-arrested, ligand-expressing
third-party cells) induce a greater extent of carcinoma cell death
in vitro in comparison to non-cross-linked agonists31 but no
mechanistic basis is available. In the context of CD40, our present
ﬁndings in combination with previous observations suggest that
these differences are not only based on TRAF3 stabilisation
capacity but also concomitant activation of the Nox subunit
p40phox.13,34 The ability to activate TRAF3/Nox determines
whether ROS induction, and subsequently apoptosis, is achieved
or not. We have therefore provided molecular evidence for the
importance of the quality of CD40 receptor engagement in
determining the functional outcome of receptor ligation.8,42 By
understanding why mCD40L is more pro-apoptotic in comparison
to non-apoptotic soluble agonists, we have consequently been
able to compensate for the inability of soluble agonist to kill
efﬁciently by combining therapy with a Trx-1 inhibitor, which
rendered the soluble agonist functionally equivalent to mCD40L.
This not only has important therapeutic implications, particularly
as this was achieved using a clinically-tested inhibitor, but also
provides evidence that engagement of the TRAF3/Nox pathway to
increase ROS is essential for apoptosis.
NADPH oxidase (Nox) is an oxidoreductase that exists as a
plasma membrane complex consisting of subunits p40-, p47-, p67,
p20 and gp91-phox. When the subunits are modiﬁed by events
such as protein phosphorylation, they transfer electrons from
NADH to oxygen to form ROS.33 p40phox has been shown to play
a critical co-activatory role in Nox-mediated ROS generation, with
one study demonstrating a direct interaction between TRAF3 and
p40phox following CD40 over-expression in mammalian B cells.34
No previous role for p40phox has been reported in epithelial cells,
but based on our results, we predict a direct TRAF3/p40phox
interaction occurs following TRAF3 stabilisation on the cytoplas-
mic tail of CD40. TRAF3 is essential for p40phox phosphorylation
and subsequent activation of ASK1, so TRAF3 and the Nox system
are central in apoptosis induction. As p40phox is a Trx binding
protein, also known as Trx binding protein-1 (tbp-1), it may play a
role in negative regulation of Trx.35,43 Thus, it is possible that
p40phox not only mediates ROS release, but also acts as a
negative regulator of Trx, which may explain why we observed a
progressive decrease in Trx expression in carcinoma cells treated
with mCD40L. We also observed that Nox function is critical in
TRAF3 stabilisation itself, which indicates a positive feedback loop-
mediated ampliﬁcation of the proximal stages of CD40 signalling.
Therefore, the ability of mCD40L to induce death is linked with its
ability to stabilise TRAF3 and generate ROS via TRAF3-Nox
activation of ASK1, while possibly utilising p40phox/tbp-1 for Trx
negative regulation. Our observation that both Nox and ROS
inhibition block apoptosis, but only Nox blockade interferes with
TRAF3 stabilisation, suggests that ROS is critical in death signalling
but not in the initial TRAF3 induction and the feedback
ampliﬁcation.
As part of our investigation of proximal and more distal
components of the apoptotic pathway triggered by CD40, we
have conﬁrmed a critical role for TRAF3-mediated activation of
JNK/AP-1 in apoptosis8,13 and shown that TRAF3 and JNK/AP-1
regulate the expression of the pro-apoptotic Bcl-2 members Bak/
Bax and the induction of MOMP. JNK can be suppressed by
Gluthathione S-Transferase (GSTp) until GSTp is oxidised by ROS,44
and JNK activation is often linked to pro-apoptotic Bcl-2 protein
expression.45 It is possible that CD40-mediated activation of JNK/
AP-1 occurs via ROS driven mechanisms, which may cause release
of GSTp and subsequent Bak-Bax expression and MOMP. JNK
activation also occurs following phosphorylation by MKK4 with
such a response mediated by oxidative stress.46 Caught between
JNK activation for apoptosis induction and MAPKKK activation for
cell proliferation, it is not surprising that MKK4 has been
suggested to have both tumour suppressive and oncogenic
functions.47 Similarly, transient JNK expression initiates pro-
survival responses whereas sustained JNK activation drives
Figure 8. CD40-mediated apoptosis in carcinoma cells. Schematic
diagram of the signalling pathway that underpins mCD40L-
mediated, tumour cell-speciﬁc apoptosis. Unlike CD40 engagement
by soluble agonist that does not adequately activate the receptor to
stabilise TRAF3 and initiate signalling, ligation of CD40 by mCD40L
recruits and upregulates TRAF3 and activates p40phox to induce
rapid ROS elevation – which appears to be essential for TRAF3
stabilisation. The generated ROS mediates the oxidation and
inactivation of Trx (Trx-1), permitting activation of ASK-1 and
subsequent phosphorylation of MKK4 and JNK to activate the JNK/
AP-1 cascade which is responsible for the induction of Bax and Bak
expression. This triggers the intrinsic, cytochrome c-driven, caspase-
9 dependent mitochondrial pathway that drives apoptosis.
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apoptosis.20,48,49 Therefore, both JNK and MKK4 may represent a
‘double-edged sword’ in cancer. Although MKK7 can also be
critical in activation of JNK50 and JNK activation is often regulated
by MKK4 and/or MKK7 following their activation by ASK1,51,52 we
could neither detect activation of MKK7, nor did MKK7 knockdown
showed any inﬂuence on mCD40L killing. Instead, we have
demonstrated that MKK4 regulates mCD40L-induced apoptosis
via JNK activation and this is regulated by TRAF3. It is also
important to emphasise that despite the wealth of publications
describing the role of critical pro-apoptotic mediators, such as
ASK1 (discussed below), MKK4/7 and/or JNK and their interactions
in the context of apoptotic signalling, the present study is the ﬁrst
to investigate the expression and functional roles of such
signalling mediators in a system that a) is based on endogenous
protein expression and does not involve any ‘artiﬁcial’ over-
expression, and b) is performed using cells of epithelial origin.
Although the importance of ASK1 in apoptosis triggered by
TNFR members has been reported,31 this is the ﬁrst such
demonstration for CD40. More importantly, CD40 not only
activates ASK1 but concurrently causes down-regulation of Trx
expression; to our knowledge a ﬁrst such demonstration for a
TNFR member. ASK1 is a MAPKKK that is biologically inhibited by
Trx in its reduced form, but Trx oxidation by ROS permits ASK1
auto-phosphorylation at Thr845.23 Active ASK1 in turn directly
phosphorylates MKK4 and leads to JNK activation.53 We now
provide evidence that ASK1 is a critical mediator of mCD40L-
induced apoptosis via its ability to regulate activation of MKK4 and
JNK. The activation of ASK1 occurring in response to mCD40L-
driven oxidative stress, in combination with active down-
regulation of Trx (which appears to be a unique property of
CD40), explains why soluble CD40 agonists, which have a low ROS-
induction capacity, do not activate ASK1 and cannot kill carcinoma
cells efﬁciently. Hence, when soluble agonist is combined with an
inhibitor of Trx-1 and negates the requirement to raise ROS
adequately to permit ASK1 activation, the non-apoptotic agonist
becomes signiﬁcantly pro-apoptotic, which is further supported by
our ﬁnding that the combination of CD40 agonist and Trx-1
inhibitor stabilises TRAF3 as efﬁciently as does mCD40L. Moreover,
the latter ﬁnding also suggests the possibility that when the
quality of the CD40 signal is appropriate, a combination of
adequate ROS elevation as well as direct involvement of mediators
such as Nox/p40phox is essential; it is tempting to speculate that
this involvement could be dependent on the formation of a large
multi-protein complex where speciﬁc interactions (e.g. between
TRAF3 and Nox) are essential. Importantly, we have provided
evidence that like mCD40L-induced apoptosis, the cell death
response triggered by the combination of soluble CD40 agonist
and Trx inhibitor is also TRAF3-ROS-ASK1 driven, ROS-dependent
and remains tumour cell-speciﬁc and, like mCD40L, this combina-
tion is cytoprotective in normal epithelial cells.
Carcinoma cells operate under conditions of oxidative stress,
often as a consequence of malignant transformation.38 The
potential role of basal cellular ROS in determining whether
cytotoxic agents can induce apoptosis in malignant cells by
‘pushing’ them past a critical ‘lethal threshold’ has long been
suggested.29,39 There is also evidence that during the process of
malignant transformation, genetic changes that drive carcinogen-
esis (such as the activation of oncogenes) can increase basal
oxidative stress.29,54 Overcoming the inﬂuence of ROS can
determine the ability to metastasise or not55 and as a result,
malignant cells are (a) obliged to upregulate antioxidant defence
systems controlling redox balance,56,57 which explains the
increased expression of endogenous antioxidants such as Trx in
cancer,36 and (b) progressively more vulnerable to ROS-associated
insults that further augment ROS generation and/or weaken
antioxidant defences in cells.38,39 Therefore, it is clear that with
such ‘cell proliferation at a cost’, tumour cells may operate in a
‘primed’ state58 that can more readily ‘push’ them past such a
lethal threshold. However, it is widely accepted that lack of
appropriate, representative epithelial models for the study of
normal cells and their transformed epithelial counterparts has
been a difﬁcult obstacle to overcome in order to test these
hypotheses.28
Our data demonstrate that the basal, steady-state intracellular
ROS levels in vitro positively correlate with the tumour stage/grade
and the degree of malignant transformation of cells and that an
increased ROS level was associated with a more malignant
phenotype. Elevated basal ROS production in more malignant
cell lines rendered them more susceptible to extreme oxidative
stress. By contrast, normal cells showed the lowest detectable
levels of basal ROS and were highly refractory to oxidative stress.
Equally, susceptibility to CD40 coincided with basal ROS levels in
malignant cells and their vulnerability to extreme ROS-mediated
stress. This implied a direct correlation between basal ROS and
susceptibility to both CD40 and oxidative stress, suggesting that
as tumour cells maintain high ROS levels to support proliferation,
CD40 ligation ‘pushes’ cells past a critical ROS-related pro-
apoptotic threshold to induce death. By contrast, the cytoprotec-
tive ability of CD40 ligation in normal cells was striking and in
accordance with previous observations by Young and colleagues
who reported that constitutive CD40 activation has the potential
to transform cells (albeit ﬁbroblasts) in vitro,59 as well as in
agreement with the suggestion that in a normal cell setting ROS
may induce proliferation.38 Moreover, unlike malignant cells that
operate under high oxidative stress and rapidly induce Trx
expression, we have now established that normal cells not only
operate at lower basal ROS but also show little Trx expression. Our
observation that basal Trx-1 protein expression progressively
increased during culture of carcinoma cells is in support of the
reported over-expression of Trx-1 in tumour cells.36
Despite reported contrasting roles for hTERT in the regulation of
apoptosis and ROS induction,41 HU-hTERT cells displayed inter-
mediate basal ROS levels and susceptibility to apoptosis by CD40
and extreme ROS stress that was substantial, albeit not equal to
that of malignant cells. Of note, we have previously shown that
CD40 ligation can induce a small level of apoptosis in p16-
deﬁcient (HU-CDK4mut) NHU cells.16 We found that HU-hTERT
cells expressed higher levels of basal ROS and were more
susceptible to CD40-mediated apoptosis than HU-CDK4mut cells
(unpublished observations). Our ﬁndings on HU-hTERT cells mirror
our observations on HPV E6-immortalised (HU-E6) urothelial cells.
Both HU-E68 and HU-hTERT cells are highly-susceptible to CD40
death supported by the induction of pro-apoptotic Bcl-2 proteins.
Interestingly, HPV E6 is a multifunctional oncoprotein that both
inactivates p1660 and triggers hTERT activation.61 Our ﬁndings
with p16 functional-knockout cells previously16 and hTERT over-
expressers here, may provide an explanation for the observations
on HPV E6 and its ability to render urothelial cells susceptible to
CD40 killing. Certainly our previous observation that HU-hTERT
progressively lost p16 expression26 implies that the combinatorial
loss of p16 function and other hTERT-speciﬁc effects may be the
two main requirements that confer CD40 susceptibility. Therefore,
our ﬁndings have provided evidence for the importance of
malignant transformation in rendering cells susceptible to ROS-
dependent apoptosis.
In summary, our investigations have allowed us to understand
the precise molecular signature of the CD40 pathway and, using it
as a paradigm, explained how cellular redox state determines
survival versus death decisions. Using a unique epithelial model,
this study has for the ﬁrst time provided evidence for a redox
state, ROS-dependent ‘lethal pro-apoptotic threshold’ that has
been hypothesised to exist in epithelial cells28,38,58 and has been
suggested as a promising therapeutic target.29,39 The evidence for
this ‘double-edged sword’ nature of ROS in determining epithelial
cell fate explains how oxidative stress-operating malignant cells
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can be more susceptible to apoptosis, which is biologically
fundamental and opens new doors to cancer-selective therapies.
MATERIALS AND METHODS
Cell culture
Human bladder carcinoma-derived EJ cells and colorectal carcinoma-
derived HCT116 cells were cultured in a 1:1 (v/v) mixture of DMEM and
RPMI 1640 containing 5% FBS (Sigma, Dorset, UK), referred to as DR 5%
medium. NHU cells and HU-hTERT cells were established and cultured in
complete KSFM (Fisher Scientiﬁc, Loughborough, UK) as described.8,26,62
3T3neo and 3T3CD40L ﬁbroblasts13,15,16 were cultured in DMEM supple-
mented with 10% FBS and containing 0.5 mg/ml G418, with omission of
antibiotic in co-culture experiments (below).
Cloning of shRNAs constructs and expression in epithelial cells by
retroviral transduction
For the preparation of short hairpin RNA (shRNA) for target proteins TRAF3,
MKK4, MKK7, ASK1, Bax and Bak, the pSIREN-RetroQ retroviral vector
system was used according to the manufacturer’s instructions (Clontech,
Takara Bio Europe, Saint-Germain-en-Laye, France). 2-3 independent
shRNAs were designed for each target and the constructs that showed
optimal inhibition of apoptosis (Supplementary Figure 4) contained the
following sequences: 5′- GAGTCAGGTTCCGATGATC-3′ (TRAF3); TAAG
CTACTTGAACACAG (MKK7); CATGGAGCTGCAGAGGATG (Bax); TCCCAA
TCCTACAGGAGTT (MKK4); CCGACGCTATGACTCAGAG (Bak); CCCTGCATTT
TGGGAAACT (ASK1). Oligonucleotides (Euroﬁns, Euroﬁns MWG Operon,
London, UK) were designed to incorporate the TTCAAGAGA hairpin loop
sequence, BamHI and EcoRI overhangs for cloning into pSIREN-RetroQ as
well as an internal MluI restriction site to aid in selection of positive clones,
as recommended by the manufacturer. Oligonucleotides were annealed
and cloned to derive plasmids pSIR-TRAF3, pSIR-MKK4, pSIR-MKK7, pSIR-
ASK1, pSIR-Bax and pSIR-Bak. A negative (scrambled) control (pSIR-Con)
was used as supplied by Clontech (Takara Bio Europe).
PT67 ﬁbroblasts were transfected with each plasmid using Effectene
(Qiagen, Crawley, UK). Stable retrovirus-producing lines PT67-TRAF3, PT67-
MKK4, PT67-MKK7, PT67-ASK1, PT67-Bax and PT67-Bak were established by
selection in culture medium containing 2 μg/ml puromycin (Invivogen,
Toulouse, France). Retroviral transductions were performed as described
previously.12,13 EJ cells were transduced with retrovirus collected as
conditioned medium from the appropriate PT67 cell lines, followed by
selection in 0.25 μg/ml puromycin resulting in the derivation of EJ-TRAF3-
KD, EJ-MKK4-KD, EJ-MKK7-KD, EJ-ASK1-KD, EJ-Bax-KD and EJ-Bak-KD as well
as isogenic EJ-Con (scrambled control shRNA-expressing) cells.
CD40 ligation by soluble receptor agonist and mCD40L
Normal and malignant epithelial cells were treated with the agonistic anti-
CD40 mAb G28-5 at 10 μg/ml (puriﬁed from the HB-9110 hybridoma line,
purchased from the ATCC) cross-linked with afﬁnity-puriﬁed human serum
protein-adsorbed goat anti-mouse IgG at 5 μg/mL as described.8 For some
experiments the MegaCD40L preparation (Enzo, Exeter, UK) was also used.
To activate CD40 by membrane CD40L (mCD40L), 3T3neo (control) and
mCD40L-expressing 3T3CD40L ﬁbroblasts (effector cells) were growth-
arrested with Mitomycin C (Sigma) and co-cultures with epithelial (target)
cells were performed as described.12,13 3T3 cells were not growth-arrested
in experiments involving ROS detection (below). 3T3 cells were seeded at
104 or 105 cells/well in 96- or 24-well plates, respectively, and epithelial
cells were subsequently seeded onto 3T3 cells at a ratio of 0.8:1 for EJ cells
and 1:1 for NHU and HCT116 cells. Following pre-titration experiments
involving effector:target ratios 1:0.8, 1:1 and 1:1.2, optimal effector:target
ratios were determined based on either apoptosis and caspase activation
detection assays (below) for malignant cells and cytokine (IL-6) release
measurements for NHU cells.12
Functional blocking studies with pharmacological inhibitors
The AP-1 inhibitor (NDGA), NADPH oxidase inhibitor (DPI), Thioredoxin
inhibitor (PX-12), and the antioxidants N-acetyl L-cysteine (NAC) and propyl
gallate were obtained from Sigma. The JNK inhibitor (SP600125) was
obtained from Enzo. NAC was initially reconstituted in DR 5% culture
medium at 30 mM, its pH was adjusted to 7.0 using 1M NaOH solution and
was ﬁlter-sterilised before use. Other inhibitors were reconstituted in
DMSO (Sigma) or ethanol (propyl gallate) and appropriate solvent-only
controls were included in all experiments. For some experiments, cells
were treated with hydrogen peroxide (H2O2) (Sigma) diluted in culture
medium at the indicated concentrations for 48 h. The effects of H2O2 on
cell growth were quantiﬁed by measuring cell biomass using the CellTiter
96 AQueous One cell proliferation assay (Promega) and results were
expressed as % cell growth of each condition in comparison to untreated
controls, as detailed elsewhere.63
Assessment of apoptosis and effector caspase activation
Previously published guidelines regarding the use and interpretation of
assays for monitoring cell death64 have recommended that a minimum of
two assays are utilised for the detection of cell apoptosis. Apoptosis was
detected using CytoTox-Glo assay (Promega, Southampton, UK) and
caspase-3/7 activation using the SensoLyte Homogeneous AFC Caspase-
3/7 assay (Anaspec, Cambridge Bioscience, Cambridge, UK). Epithelial cells
were treated with soluble CD40 agonist or mCD40L by co-culture with
effector 3T3 cells in 96-well plates before apoptosis assays were performed
by luminescence (Cytotox-Glo, Promega) and ﬂuorescence (SensoLyte,
Anaspec) measurements were taken on a FLUOstar OPTIMA plate reader
and data analysed using MARS software (BMG Labtech, Bucks, UK). To
account for background attributable to the effector cells in co-cultures, 3T3
cells were cultured alone and their relative luminescence or ﬂuorescence
units subtracted from the representative co-culture in a pair wise fashion.
Results were presented as fold change or fold caspase activity, respectively,
of 3T3CD40L co-cultures relative to 3T3neo co-culture controls. All assays
were performed at 48 h unless otherwise stated.
Detection of ROS
6-carboxy-2',7'-dichlorodihydroﬂuorescein diacetate (H2DCFDA) (Fisher
Scientiﬁc) was used to detect reactive oxygen species (ROS). Epithelial
cells were treated with soluble CD40 agonist or mCD40L as described
above. Following CD40 ligation for 3 h, cultures of agonist treated cells or
co-cultures were washed with PBS and were then treated with 1 μM of
H2DCFDA in pre warmed (37 °C) PBS for 30 min at 37 °C in 5% CO2.
Fluorescence was then measured by either ﬂow cytometry on a Guava
EasyCyte (Millipore, Watford, UK) or by spectrophotometry on a FLUOstar
OPTIMA plate reader and expressed as median ﬂuorescence intensity (MFI)
or fold change (following background subtraction) with respect to controls,
respectively.
Immunoblotting (Western blot) analysis
Whole-cell lysates were prepared (Bugajska et al.,8) separated by 4-12%
SDS-PAGE, followed by electroblotting using Immobilon-FL polyvinylidine
diﬂuoride (PVDF) membrane (FDR-523-020Q) (Fisher Scientiﬁc) and probed
with the following antibodies: TRAF3 (sc-949/C20), cytochrome c (sc-7159)
(Santa Cruz, supplied by Insight Bio, Wembley, UK), phospho-MKK4
(Ser457) (#4514 (C36C11)), phospho-MKK7 (Ser271/Thr275) (#4171),
phospho-ASK1 (Thr845) (#3765), phospho-JNK (Thr183/Tyr185) (255 (G9)),
Thioredoxin-1 (#2285S), phospho-p40phox (Thr154) (#4311) (Cell Signalling
Technologies, supplied by New England Biolabs, Herts, UK), Bak (AF816),
Bax (2282-MC-100 (YTH-2D2)), and Bcl-2 (2291-MC-100 (YTH-8C8) (R&D
Systems, Abingdon, UK). It should be noted that as lysates were prepared
from 3T3neo/3T3CD40L and epithelial cell co-cultures, sample loading
was corrected and adjusted for epithelial cells. This was carried out
according to reactivity with human-speciﬁc anti-CK18 (Sigma Scientiﬁc)
or anti-CK8 (Fisher) antibodies (and not using antibodies detecting
non-phosphorylated intracellular signalling mediators), as explained
elsewhere.13 Antibody binding was detected by incubation with goat
anti-rabbit immunoglobulin conjugated to IRDye
®
800 (Tebu-bio, Cambs,
UK) or goat anti-mouse immunoglobulin conjugated to Alexa Fluor 680
(Invitrogen, Paisley, UK). Immunolabelling was visualised using an Odyssey
infra-red imaging system (LiCor, Cambs, UK) and densitometry performed
for representative blots (Supplementary Figure 5) using the manufacturer’s
(LiCor) software.
Sub-cellular fractionation
Mitochondrial and cytoplasmic fractions were isolated from co-cultures
performed in 10 cm2 dishes (3 × 106 3T3 cells and 2.7 × 106 epithelial cells)
for 24 h using the mitochondrial isolation kit (Millipore #MT1000) as
instructed by the manufacturer. Mitochondrial pellets were lysed and
processed as for the preparation of whole cell lysates. Successful
mitochondrial and cytoplasmic fractionation was conﬁrmed by detection
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of Bcl-2 and GAPDH, respectively. All primary antibodies were supplied
with the kit (Millipore) and immunoblotting using appropriate secondary
antibodies was performed as detailed above.
Statistics
Mean values and standard deviation (s.d.) were used as descriptive
statistics. Two-tailed, paired or non-paired Student’s t-tests, and where
appropriate ANOVA (with post tests), were used for evaluation of statistical
signiﬁcance. For graphical purposes *Po0.05, **Po0.01 and ***Po0.001.
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